Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...

Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity drug Zepbound from the list of medicines it covers for reimbursement ...

(Bloomberg) -- Eli Lilly & Co. is using its runaway success in obesity as a bridge ... for trials to test its popular ...

Eli Lilly said its Zepbound obesity drug helped patients reduce ... freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on ...

U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral weight-loss drug news and BMO cut its rating for the Danish drug developer's ...

A study of two blockbuster weight-loss drugs showed that users of Eli Lilly's Zepbound lost just over ... to our mission of empowering investor success. We provide a platform for our authors ...

Eli Lilly on Thursday posted better-than-expected first quarter revenue and profit, although sales of its popular weight-loss drug, Zepbound, came in slightly below Wall Street estimates, sending its ...

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, Wegovy, Mounjaro and Zepbound, the pharmaceuticals giant said Thursday.

Looking for undervalued stocks? Check out three top undervalued stocks to buy now in May, 2025 to boost your portfolio.

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...